OKYO Pharma Limited Stock Price

NasdaqCM:OKYO Community·US$96.7m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
2 Fair Values set on narratives written by author

Create a narrative

OKYO Share Price Performance

US$2.72

1.60 (142.86%)

US$2.72

1.60 (142.86%)

US$2.72

Thu, 6 Nov 25

Share PriceUS$2.72

OKYO Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Medium-low risk with mediocre balance sheet.

6 Risks

1 Reward

View Full Analysis

OKYO Pharma Limited Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

n/a

: -0.13
: 0%
: 0%
: 0%

View Full Analysis

About OKYO

Founded: 2007
Employees: 4
CEO: Gary Jacob
WebsiteView website: okyopharma.com

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.